Zomedica to Develop Gastrointestinal Testing Panel for TRUFORMA™Three new assays to be added to the five assays currently under development. The dynamic range of the canine TRUFORMA fT4 assay is 7.4-77.2 pmol/L compared to the Siemens IMMULITE Veterinary Free T4 assay dynamic range of 3.9-77.2 pmol/L. Stephanie Morley, President & Chief Medical Officer of Zomedica, commented: "Setting the date for the availability of TRUFORMA is the culmination of a dream for me. Zomedica (NYSE: ZOM) is a stock that is absolutely on fire right now.Indeed, ZOM stock has provided investors with a year-to-date return of 880% at the time of publication. However, it’s just around the corner, and it will be a significant month for Zomedica. In the release, ZOM reminded investors that the TRUFORMA diagnostics platform is protected by around 70 issued and pending patents. Anyways, I’m predicting this is a good stock to buy and hold up to the announcement. Miami Beach, Florida--(Newsfile Corp. - October 1, 2019) - Zomedica, Inc. (NYSE American: ZOM) (TSXV: ZOM) is getting closer to commercializing its first potentially industry-changing product, TRUFORMA™, a point of care diagnostic platform with initial assays used to diagnose thyroid and adrenal disorders in dogs and cats. Zomedica has been a hot topic as of late and for good reason. Zomedica expects to begin commercial sales of TRUFORMA on March 30, 2021.About Zomedica Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is … March 8, 2021 - 6:05 am. PMN Press Releases; GlobeNewswire Releases; Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™ Certain assays under development are believed to be the first ever for use at the point-of-care and the first ever available in veterinary medicine . While the sales focus for 2021 will be on creating an installed base of TRUFORMA instruments, each of these instruments provides a razor/razor blade opportunity not only as it relates to the initial five assays that we intend to make available in 2021, but to the expanding family of assays that Zomedica expects to develop and release over the next several years. Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™. www.google.com. Application Filed: 2019-09-10. Zomedica Will Launch TRUFORMA Soon. In the press release, Zomedica said that it plans on beginning commercialization of its point-of-care diagnostics platform, known as TRUFORMA, on March 30, 2021. Buy Denon AVR-S700W 7.2-Channel Network AV Receiver with Bluetooth and Wi-Fi (Discontinued by Manufacturer): Receivers - Amazon.com FREE DELIVERY possible on eligible purchases Zomedica Corp.(NYSE:ZOM): Pet care stocks have been on a solid run of late as homebound lifestyles have caused more Americans to adopt pets. TRUFORMA Zomedica Pharmaceuticals Corp. USPTO Trademarks › Zomedica Pharmaceuticals Corp. › Truforma Application #88610993. ZOM stock is worth as much as $3.61 following its Truforma product launch. ANN ARBOR, Mich., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has signed an agreement with Miller Veterinary Supply (“Miller”) for the distribution of TRUFORMA™, Zomedica’s first product, planned to begin sales on March 30, 2021. The big news for Zomedica and any investors who have interest in this company as a long-term holding is Truforma. The company’s very first commercial product, Truforma is a … March may seem like a long way off. ANN ARBOR, Mich., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of … TRUFORMA(R) Progressing Toward Commercialization . Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™.Dr. Press Release Zomedica CEO Issues Shareholder Letter as TRUFORMA(TM) Nears Commercialization Published: Jan. 18, 2021 at 11:14 a.m. ET Bragdon joined Zomedica in 2019 as Vice President of Veterinary Affairs. On Friday, Zomedica released its Q4 and year end 2020 financial results, and the news was somewhat optimistic for a company that has zero revenues to date… Zomedica and its investors prepare for the release of its diagnostic software platform Truforma on March 30th. Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™. TRUFORMA (TM) Technology Overview Video. Zomedica is a winner with its pet lab product and cash balance. Zomedica Nears Major Catalyst In TRUFORMA Product Launch (NYSEMKT:ZOM) Zomedica is a development-stage company that focuses on the unmet diagnostic and therapeutic treatment needs of clinical veterinarians. 08.03.2021 - TRUFORMA Progressing Toward CommercializationANN ARBOR, Mich., March 08, 2021 (GLOBE NEWSWIRE) - Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or … Zomedica is on the verge of developing certain assays that might be the first ever available in veterinary medicine. ZOM Stock Climbs on Target Commercialization Date. Against this backdrop, we think shares of veterinary diagnostic company Zomedica Corp. (ZOM) are well-positioned to gain ahead of the company’s forthcoming launch of its flagship Truforma point-of-care diagnostic platform in March. ANN ARBOR, Mich., March 08, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it has effected the exchange of all of its outstanding Series 1 Preferred Shares … Zomedica appears to be in solid financial shape while it waits for the launch of Truforma to shift into high gear. Zomedica Signs TRUFORMA Distribution Agreement With Miller Veterinary Supply. Verification data comparing the canine TRUFORMA cortisol assay to the Siemens IMMULITE Cortisol reference lab assay showed high correlation (R=0.97). The feasibility and design phases of the TRUFORMA ACTH assay have been completed, with verification expected to begin in the near future. ANN ARBOR, Mich., July 21, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or … Shares of Zomedica Corp. (ZOM) soared up to 50% in the premarket following the announcement of the expected commercialization date for its TRUFORMA™ point-of-care diagnostic platform. Truforma. Trademark Application Details. Not too long ago, investors received an update surrounding the launch of TRUFORMA. Sales representatives of Miller Veterinary Supply, Zomedica’s distribution partner, also have completed their initial training program. Zomedica hasn't released information regarding those, so it's unclear if a potential hiccup could put the product release date in jeopardy. In further news, the first group of direct Zomedica field personnel have completed their training in anticipation of the commercial release of TRUFORMA. Author of the article: GlobeNewswire.